China SXT Pharmaceuticals (SXTC) Competitors

$1.60 +0.01 (+0.63%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$1.59 -0.01 (-0.56%)

As of 07:03 AM Eastern

SXTC vs. FBLG, APVO, ACXP, FLGC, and BGMS

Should you buy China SXT Pharmaceuticals stock or one of its competitors? MarketBeat compares China SXT Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China SXT Pharmaceuticals include FibroBiologics (FBLG), Aptevo Therapeutics (APVO), Acurx Pharmaceuticals (ACXP), Flora Growth (FLGC), and Cyclacel Pharmaceuticals (BGMS). These companies are all part of the "pharmaceutical products" industry.

How does China SXT Pharmaceuticals compare to FibroBiologics?

China SXT Pharmaceuticals (NASDAQ:SXTC) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

China SXT Pharmaceuticals' return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
FibroBiologics	N/A	-767.07%	-195.56%

China SXT Pharmaceuticals has higher revenue and earnings than FibroBiologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.74M	0.88	-$3.30M	N/A	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

China SXT Pharmaceuticals has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 6,751.85%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, FibroBiologics had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 4 mentions for FibroBiologics and 3 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.96 beat FibroBiologics' score of 0.47 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China SXT Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

China SXT Pharmaceuticals beats FibroBiologics on 7 of the 12 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Aptevo Therapeutics?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

China SXT Pharmaceuticals has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

China SXT Pharmaceuticals' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Aptevo Therapeutics	N/A	-190.74%	-112.83%

China SXT Pharmaceuticals has higher revenue and earnings than Aptevo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.74M	0.88	-$3.30M	N/A	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$1.77 thousand	N/A

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 2 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.96 beat China SXT Pharmaceuticals' score of 0.96 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
China SXT Pharmaceuticals	Positive
Aptevo Therapeutics	Positive

Summary

China SXT Pharmaceuticals beats Aptevo Therapeutics on 7 of the 11 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Acurx Pharmaceuticals currently has a consensus price target of $31.00, suggesting a potential upside of 1,497.94%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

China SXT Pharmaceuticals' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
China SXT Pharmaceuticals	N/A	N/A	N/A

China SXT Pharmaceuticals has higher revenue and earnings than Acurx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
China SXT Pharmaceuticals	$1.74M	0.88	-$3.30M	N/A	N/A

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Acurx Pharmaceuticals had 7 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 10 mentions for Acurx Pharmaceuticals and 3 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.96 beat Acurx Pharmaceuticals' score of 0.39 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acurx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China SXT Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Acurx Pharmaceuticals and China SXT Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Flora Growth?

Flora Growth (NASDAQ:FLGC) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

China SXT Pharmaceuticals has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. China SXT Pharmaceuticals' return on equity of 0.00% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
China SXT Pharmaceuticals	N/A	N/A	N/A

Flora Growth has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, China SXT Pharmaceuticals had 3 more articles in the media than Flora Growth. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 0 mentions for Flora Growth. China SXT Pharmaceuticals' average media sentiment score of 0.96 beat Flora Growth's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Flora Growth	Neutral
China SXT Pharmaceuticals	Positive

China SXT Pharmaceuticals has lower revenue, but higher earnings than Flora Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A
China SXT Pharmaceuticals	$1.74M	0.88	-$3.30M	N/A	N/A

Flora Growth presently has a consensus price target of $30.00, indicating a potential upside of 575.68%. Given Flora Growth's stronger consensus rating and higher probable upside, research analysts clearly believe Flora Growth is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

China SXT Pharmaceuticals beats Flora Growth on 9 of the 14 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cyclacel Pharmaceuticals has a beta of -0.49, meaning that its stock price is 149% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

In the previous week, Cyclacel Pharmaceuticals and Cyclacel Pharmaceuticals both had 3 articles in the media. Cyclacel Pharmaceuticals' average media sentiment score of 1.43 beat China SXT Pharmaceuticals' score of 0.96 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China SXT Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than China SXT Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$747K	7.76	-$3M	-$4.50	N/A
China SXT Pharmaceuticals	$1.74M	0.88	-$3.30M	N/A	N/A

China SXT Pharmaceuticals' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-58.15%	-48.99%
China SXT Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cyclacel Pharmaceuticals beats China SXT Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get China SXT Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTC vs. The Competition

Export

Metric	China SXT Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.53M	$3.06B	$6.34B	$12.37B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	N/A	18.70	20.66	25.63
Price / Sales	0.88	271.92	547.02	76.59
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	0.00	4.42	9.93	6.97
Net Income	-$3.30M	$72.19M	$3.55B	$333.62M
7 Day Performance	-3.96%	-0.43%	1.69%	1.09%
1 Month Performance	-13.98%	-0.96%	0.48%	3.08%
1 Year Performance	-99.32%	45.81%	39.38%	35.68%

China SXT Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTC China SXT Pharmaceuticals	1.2363 of 5 stars	$1.60 +0.6%	N/A	-99.4%	$1.53M	$1.74M	N/A	90	Short Interest Decrease
FBLG FibroBiologics	3.6452 of 5 stars	$1.13 +2.3%	$74.00 +6,477.8%	-93.5%	$5.86M	N/A	N/A	10	Gap Down
APVO Aptevo Therapeutics	1.015 of 5 stars	$4.86 +0.6%	N/A	-96.0%	$5.74M	N/A	N/A	50	Earnings Report Upcoming Earnings
ACXP Acurx Pharmaceuticals	2.0124 of 5 stars	$1.96 -4.4%	$31.00 +1,481.6%	-73.6%	$5.61M	N/A	N/A	3	Earnings Report Analyst Revision
FLGC Flora Growth	1.6131 of 5 stars	$5.35 +15.1%	$30.00 +460.7%	-83.6%	$5.60M	$57.61M	N/A	280	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTC) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China SXT Pharmaceuticals (SXTC) Competitors

SXTC vs. FBLG, APVO, ACXP, FLGC, and BGMS

How does China SXT Pharmaceuticals compare to FibroBiologics?

Summary

How does China SXT Pharmaceuticals compare to Aptevo Therapeutics?

Summary

How does China SXT Pharmaceuticals compare to Acurx Pharmaceuticals?

Summary

How does China SXT Pharmaceuticals compare to Flora Growth?

Summary

How does China SXT Pharmaceuticals compare to Cyclacel Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC vs. The Competition

China SXT Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China SXT Pharmaceuticals (SXTC) Competitors

SXTC vs. FBLG, APVO, ACXP, FLGC, and BGMS

How does China SXT Pharmaceuticals compare to FibroBiologics?

Is SXTC or FBLG more profitable?

Which has better earnings and valuation, SXTC or FBLG?

Which has more volatility & risk, SXTC or FBLG?

Do analysts rate SXTC or FBLG?

Does the media prefer SXTC or FBLG?

Do insiders & institutionals hold more shares of SXTC or FBLG?

Summary

How does China SXT Pharmaceuticals compare to Aptevo Therapeutics?

Do analysts rate SXTC or APVO?

Which has more risk and volatility, SXTC or APVO?

Is SXTC or APVO more profitable?

Which has stronger valuation and earnings, SXTC or APVO?

Do insiders & institutionals believe in SXTC or APVO?

Does the media favor SXTC or APVO?

Summary

How does China SXT Pharmaceuticals compare to Acurx Pharmaceuticals?

Do analysts rate ACXP or SXTC?

Which has more volatility & risk, ACXP or SXTC?

Is ACXP or SXTC more profitable?

Which has higher earnings and valuation, ACXP or SXTC?

Do institutionals & insiders believe in ACXP or SXTC?

Does the media favor ACXP or SXTC?

Summary

How does China SXT Pharmaceuticals compare to Flora Growth?

Is FLGC or SXTC more profitable?

Which has more volatility & risk, FLGC or SXTC?

Do insiders and institutionals believe in FLGC or SXTC?

Does the media refer more to FLGC or SXTC?

Which has better earnings and valuation, FLGC or SXTC?

Do analysts prefer FLGC or SXTC?

Summary

How does China SXT Pharmaceuticals compare to Cyclacel Pharmaceuticals?

Do insiders and institutionals believe in BGMS or SXTC?

Which has more volatility & risk, BGMS or SXTC?

Does the media refer more to BGMS or SXTC?

Which has better earnings and valuation, BGMS or SXTC?

Is BGMS or SXTC more profitable?

Do analysts prefer BGMS or SXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC vs. The Competition

China SXT Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools